Agonists of PPAR gamma (PPAR-γ) including rosiglitazone and pioglitazone are commonly suggested to treat insulin resistance and hyperglycemia [127] and to reduce the activation of spinal nociceptive neurons in type II diabetic rat models [128]. The gene discussed is PPARG; the disease is Insulin resistance.